赛托瑞医疗 CYTX 深 沪
等待开盘 09-19 09:30:00 美东时间
0.2077
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 0.2077
- 总市值 376.46万
- 52周最高 562.50
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 153.00
- 委 比 0.00%
- 总股本 1812.50万
- 历史最高 554625.00
- 量 比 0
- 振 幅 0.00%
- 历史最低 153.00
- 每 手 1
- 风险率 0.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多D. Boral Capital Maintains Buy on Plus Therapeutics, Maintains $5 Price Target
D. Boral Capital analyst Jason Kolbert maintains Plus Therapeutics (NASDAQ:PSTV) with a Buy and maintains $5 price target.
09-18 19:57
D. Boral Capital Upgrades Plus Therapeutics to Buy, Announces $5 Price Target
D. Boral Capital analyst Jason Kolbert upgrades Plus Therapeutics (NASDAQ:PSTV) from Hold to Buy and announces $5 price target.
09-03 19:40
CytomX Therapeutics to Present at Upcoming September Investor Conferences
<p align="justify">CytomX Therapeutics announced that its management will participate in three investor conferences in September 2025: the Cantor Global Healthcare Conference, H.C. Wainwright 27th Annual Global Investment Conference, and Morgan Stanley 23rd Annual Global Healthcare Conference, all held in New York City. Additionally, live webcasts of their presentations will be available on CytomX’s website, www.cytomx.com. The company focuses on...
08-28 12:00
Plus Therapeutics Secures Nasdaq Compliance Extension
Plus Therapeutics ( ($PSTV) ) has shared an update. On August 22, 2025, Plus Th...
08-26 18:58
Plus Therapeutics Awaits Nasdaq Compliance Confirmation
Plus Therapeutics ( ($PSTV) ) has provided an update. On June 3, 2025, Plus The...
08-15 05:15
Plus Therapeutics Q2 EPS $(0.01) Beats $(0.18) Estimate, Sales $1.390M Miss $1.486M Estimate
Plus Therapeutics (NASDAQ:PSTV) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $(0.18) by 94.44 percent. This is a 98.59 percent increase over losses of $(0.71) per share from
08-15 04:29
Plus Therapeutics shares are trading lower after the company filed a prospectus to offer 33 million shares.
Plus Therapeutics shares are trading lower after the company filed a prospectus...
08-13 22:46
Plus Therapeutics Granted Continued Nasdaq Listing
An announcement from Plus Therapeutics ( ($PSTV) ) is now available. On June 3,...
08-13 18:28
CytomX Therapeutics Provides Update on CX-2051 Phase 1 Study
CytomX Therapeutics has enrolled 73 colorectal cancer patients in their CTMX-2051-101 Phase 1 study, aiming to provide a data update in Q1 2026. The study remains active with patients continuing to receive CX-2051 across all expansion doses. A single Grade 5 treatment-related acute kidney injury occurred in a patient with a complex medical history, reported to the FDA. The Safety Review Committee supported continued study execution. CX-2051 is a ...
08-13 12:00
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Soligenix (NASDAQ:SNGX) shares rose 192.0% to $3.65 during Thursday's ...
08-01 01:08
